Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

advanced Breast Cancer

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of Advanced Breast Cancer During Pregnancy

Broader topic: Breast Cancer

Source population
Not part of this definition
Disease extent
advanced
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from an NCI treatment-summary heading. NCI PDQ is an evidence summary, not a practice guideline, and only the dimensions the heading states are part of this definition.
      source wording
      Treatment of Advanced Breast Cancer During Pregnancy

      Study evidence for this setting

      0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      2015-02-03 · Ibrance (palbociclib) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-breast-cancer-advanced-c4e7a92e
      event id
      fda-a80e503b68697372
      event date
      2015-02-03
      event kind
      accelerated-approval
      drug or regimen
      Ibrance (palbociclib)
      source indication text
      In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease
      match phrase
      advanced breast cancer
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-f1c1411e2a103eb4331d
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2017-03-31 · Ibrance (palbociclib) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-breast-cancer-advanced-c4e7a92e
      event id
      fda-87e1462b06d274dc
      event date
      2017-03-31
      event kind
      traditional-approval
      drug or regimen
      Ibrance (palbociclib)
      source indication text
      In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease
      match phrase
      advanced breast cancer
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-f1c1411e2a103eb4331d
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice